Salarius Pharmaceuticals, Inc. Material Event - What Happened

Hey there! Let's break down what's going on with Salarius Pharmaceuticals, Inc. in a way that makes sense, without all the confusing business talk. Think of this as me explaining the news to you over coffee.

---

1. What happened? (The actual event, in plain English)

Okay, so Salarius Pharmaceuticals just announced something pretty significant. They received a notice from Nasdaq (the stock exchange where their shares are traded) that their stock price has fallen too low and they are at risk of being delisted.

Specifically, their common stock's closing bid price has been below the required $1.00 per share for the last 30 consecutive business days. This is a big deal because it means their shares might no longer be traded on Nasdaq, which is a major exchange.

What makes this even more critical is that Salarius isn't eligible for the usual grace period to fix the problem. This is because they already did a "reverse stock split" (a way to artificially boost the stock price by reducing the number of shares) within the past year, and they are under a "Mandatory Panel Monitor" by Nasdaq.

Unless they successfully appeal this decision, Nasdaq plans to suspend their securities and delist them starting January 9, 2026.

2. When did it happen?

Salarius received this official notice from Nasdaq on December 31, 2025. They then publicly announced it in a filing on January 2, 2026.

3. Why did it happen? (The backstory)

To understand why this is happening, you need a little context. Salarius is a company that focuses on developing new medicines, especially for tough diseases like cancer. Companies listed on major stock exchanges like Nasdaq have to follow certain rules to stay listed. One of these rules is maintaining a minimum stock price, usually $1.00 per share.

Salarius's stock price has consistently traded below this $1.00 threshold. This isn't a new problem; the fact that they did a reverse stock split in the past year suggests they've been struggling with their stock price for a while. A reverse stock split is often a last-ditch effort to get the price back up, but if it doesn't hold, it signals deeper issues. Because they've already used that option and the price still fell, Nasdaq is taking a stricter stance, denying them the typical 180-day period to regain compliance.

4. Why does this matter? (The "so what?")

This is definitely bad news for Salarius. Delisting from Nasdaq is a serious setback:

• Loss of Prestige: Being on Nasdaq gives a company credibility and visibility. Moving to a less prominent exchange (like the over-the-counter or "OTC" markets) can make the company seem less stable or trustworthy.
• Harder to Trade: Shares traded on OTC markets are often less liquid, meaning it can be harder for investors to buy or sell them quickly. This can also lead to wider price swings.
• Difficulty Raising Money: It becomes much harder for the company to raise additional capital from investors if their stock isn't on a major exchange, which is crucial for biotech companies that need a lot of funding for drug development.
• Impact on Reputation: It signals to the market that the company is struggling to meet basic listing requirements, which can erode investor confidence.

In short, it impacts their future plans, their ability to develop new drugs, and ultimately, their potential success and survival as a publicly traded company.

5. Who is affected?

A few different groups will feel the ripple effects of this news:

• Investors/Shareholders: People who own stock in Salarius are directly affected. The value of their shares could drop significantly, and it might become harder to sell them if the company is delisted.
• Salarius Employees: Their jobs and the company's future direction are now under a cloud of uncertainty.
• The Company Itself: Its ability to operate, fund research, and attract new investors is severely hampered.
• Patients: While not directly impacted by the stock price, if the company struggles financially due to delisting, it could slow down or halt the development of potential new treatments they are working on.

6. What happens next? (Looking ahead)

So, what's on the horizon?

• Immediately: Salarius intends to appeal Nasdaq's decision by January 7, 2026. This appeal will temporarily stay (pause) the delisting process, meaning their shares won't be suspended on January 9th, at least not yet.
• In the near future: They will present their plans to a Nasdaq Hearings Panel to explain how they intend to get their stock price back above $1.00. This could involve another reverse stock split (though they just did one), or other strategic moves to boost investor confidence.
• Longer term: The Hearings Panel will make a decision. There's no guarantee they will rule in Salarius's favor. If the appeal is successful, Salarius might get more time to regain compliance. If it's unsuccessful, the delisting will proceed, and their shares will move to an OTC market.

7. What should investors/traders know? (Practical takeaways)

For those of you watching the stock or thinking about investing:

• Extreme Risk: This situation significantly increases the risk associated with Salarius stock. The possibility of delisting is very real.
• Watch the Stock Price: Expect the stock price to be highly volatile (swinging up and down a lot) as investors react to the news and the outcome of the appeal.
• Delisting Consequences: Understand that if delisted, your shares will likely trade on a less liquid market, which can make them harder to sell and potentially reduce their value.
• Appeal is Critical: The outcome of the appeal is the next major catalyst. A favorable decision might provide a temporary reprieve, but an unfavorable one could lead to immediate delisting.
• Underlying Issues: A persistent low stock price and delisting threat often point to deeper concerns about the company's financial health, drug pipeline, or overall business strategy.
• Do Your Homework: Before making any decisions, always do your own research. This report gives you the basics, but dig deeper into the company's official announcements and expert analyses.

---

Hopefully, this helps you understand what's going on with Salarius Pharmaceuticals without needing a finance degree!